Femasys Inc (FEMY)
Femasys Inc. is a biomedical company focused on therapeutic and diagnostic solutions for unmet women’s healthcare needs in the United States and international markets. Its portfolio includes FemaSeed for intratubal insemination, FemVue for ultrasound-based fallopian tube assessment, FemCerv for endocervical tissue sampling in cervical cancer diagnosis, FemCath for selective fallopian tube evaluation, and FemChec for controlled contrast generation in fallopian tube diagnosis. The company is also developing FemBloc, a non-surgical permanent birth control solution. Femasys markets its products to reproductive endocrinologists, gynecological physicians, and related women’s healthcare organizations. Incorporated in 2004, the company is headquartered in Suwanee, Georgia. FEMY is the common stock of Femasys Inc. and trades on the NASDAQ exchange.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-FEMY
|
$3.04
|
18.6% Upside
|
Undervalued
|
$14.33
|
459.9% Upside
|
Bargain
|
Weak
|
0.0%
|
November 17, 2026
|
5.3x
|
9.2x
|
21.44 M
|
24.536 M
|
18.4%
|
87.7%
|
-19.8
|
153.6%
|
